Inventor · disambiguated record
Andrew J. Murphy
Also filed as: MURPHY ANDREW · MURPHY ANDREW J · MURPHY ANDREW J M
360 granted patents·178 pending applications·5,986 citations·filing 1994–2025
99Inventor score
Files withREGENERON PHARMA472MACDONALD LYNN12CADUS TECHNOLOGIES INC10MURPHY ANDREW J7CADUS PHARMACEUTICAL CORP6
Top patents by PatentIndex Score
538 records- 0199US10412940B2Mice expressing a limited immunoglobulin light chain repertoireREGENERON PHARMA·Filed 2018·Granted Sep 17, 2019·38 cites·15 claims
- 0299US9844212B2Human lambda light chain miceREGENERON PHARMA·Filed 2017·Granted Dec 19, 2017·15 cites·30 claims
- 0399US9226484B2Human lambda light chain miceREGENERON PHARMA·Filed 2015·Granted Jan 5, 2016·31 cites·7 claims
- 0499US9206263B2Method of making antibodies using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·33 cites·35 claims
- 0599US9206262B2Method of cloning a lambda light chain variable domain using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·20 cites·15 claims
- 0699US9163092B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted Oct 20, 2015·36 cites·20 claims
- 0799US9150662B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted Oct 6, 2015·31 cites·20 claims
- 0899US9066502B2Hybrid light chain miceREGENERON PHARMA·Filed 2013·Granted Jun 30, 2015·36 cites·13 claims
- 0999US9029628B2Human lambda light chain miceREGENERON PHARMA·Filed 2013·Granted May 12, 2015·37 cites·21 claims
- 1099US9006511B2Human lambda light chain miceREGENERON PHARMA·Filed 2013·Granted Apr 14, 2015·45 cites·7 claims
- 1199US8754287B2Mice that make heavy chain antibodiesMACDONALD LYNN·Filed 2010·Granted Jun 17, 2014·159 cites·14 claims
- 1299US8697940B2ADAM6 miceREGENERON PHARMA·Filed 2013·Granted Apr 15, 2014·114 cites·21 claims
- 1399US8642835B2ADAM6 miceMACDONALD LYNN·Filed 2012·Granted Feb 4, 2014·133 cites·23 claims
- 1499US7105348B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2002·Granted Sep 12, 2006·355 cites·15 claims
- 1599US6596541B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2001·Granted Jul 22, 2003·996 cites·17 claims
- 1699US6586251B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2000·Granted Jul 1, 2003·505 cites·14 claims
- 1798US10694725B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Jun 30, 2020·15 cites·16 claims
- 1898US10577430B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Mar 3, 2020·15 cites·16 claims
- 1998US9987500B2Human antibodies to PD-1REGENERON PHARMA·Filed 2015·Granted Jun 5, 2018·126 cites·10 claims
- 2098US9944716B2ADAM6 miceREGENERON PHARMA·Filed 2015·Granted Apr 17, 2018·17 cites·6 claims
- 2198US9938345B2Human antibodies to PD-L1REGENERON PHARMA·Filed 2015·Granted Apr 10, 2018·37 cites·8 claims
- 2298US9850462B2Human lambda light chain miceREGENERON PHARMA·Filed 2017·Granted Dec 26, 2017·9 cites·13 claims
- 2398US9637535B2IL-33 antagonists and uses thereofREGENERON PHARMA·Filed 2014·Granted May 2, 2017·36 cites·33 claims
- 2498US9540452B2Human lambda light chain miceREGENERON PHARMA·Filed 2015·Granted Jan 10, 2017·13 cites·29 claims
- 2598US9540449B2Anti-PCSK9 antibodies with pH-dependent binding characteristicsREGENERON PHARMA·Filed 2013·Granted Jan 10, 2017·57 cites·13 claims
- 2698US9462794B2Non-human animals having a humanized signal-regulatory protein geneREGENERON PHARMA·Filed 2015·Granted Oct 11, 2016·28 cites·41 claims
- 2798US9453072B2Anti-IL-33 antibodiesREGENERON PHARMA·Filed 2014·Granted Sep 27, 2016·49 cites·20 claims
- 2898US9399683B2Human lambda light chain miceREGENERON PHARMA·Filed 2015·Granted Jul 26, 2016·14 cites·15 claims
- 2998US9334333B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted May 10, 2016·12 cites·14 claims
- 3098US9332742B2Histidine engineered light chain antibodies and genetically modified non-human animals for generating the sameREGENERON PHARMA·Filed 2015·Granted May 10, 2016·19 cites·30 claims
- 3198US9206261B2Method of making antibodies using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·19 cites·35 claims
- 3298US9193977B2Non-human animals having a humanized signal-regulatory protein geneREGENERON PHARMA·Filed 2014·Granted Nov 24, 2015·29 cites·28 claims
- 3398US9127292B2Non-human animals having a humanized signal-regulatory protein geneREGENERON PHARMA·Filed 2014·Granted Sep 8, 2015·28 cites·16 claims
- 3498US9113616B2Genetically modified mice having humanized TCR variable genesREGENERON PHARMA·Filed 2012·Granted Aug 25, 2015·67 cites·42 claims
- 3598US9079948B2Human antibodies to Fel d1 and methods of use thereofREGENERON PHARMA·Filed 2013·Granted Jul 14, 2015·83 cites·12 claims
- 3698US9043996B2Genetically modified major histocompatibility complex animalsREGENERON PHARMA·Filed 2013·Granted Jun 2, 2015·31 cites·42 claims
- 3798US9035128B2Hybrid light chain miceMACDONALD LYNN·Filed 2011·Granted May 19, 2015·59 cites·19 claims
- 3898US9018356B2Anti-ANGPTL3 antibodies and uses thereofSLEEMAN MARK W·Filed 2012·Granted Apr 28, 2015·86 cites·12 claims
- 3998US9012717B2Human lambda light chain miceMACDONALD LYNN·Filed 2011·Granted Apr 21, 2015·61 cites·13 claims
- 4098US8878001B2Humanized IL-6 and IL-6 receptorREGENERON PHARMA·Filed 2012·Granted Nov 4, 2014·38 cites·4 claims
- 4198US8847005B2Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2012·Granted Sep 30, 2014·33 cites·16 claims
- 4298US8791323B2Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouseMURPHY ANDREW J·Filed 2006·Granted Jul 29, 2014·97 cites·3 claims
- 4398US8502018B2Methods of modifying eukaryotic cellsMURPHY ANDREW J·Filed 2011·Granted Aug 6, 2013·250 cites·20 claims
- 4497US11760775B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2020·Granted Sep 19, 2023·5 cites·9 claims
- 4597US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 4697US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 4797US10905109B2ADAM6 miceREGENERON PHARMA·Filed 2018·Granted Feb 2, 2021·10 cites·13 claims
- 4897US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 4997US10676530B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptorREGENERON PHARMA·Filed 2017·Granted Jun 9, 2020·14 cites·24 claims
- 5097US10669341B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptorREGENERON PHARMA·Filed 2017·Granted Jun 2, 2020·13 cites·20 claims
Showing the top 50 of 538 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Andrew J. Murphy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →